BioMarin's Brineura Gets FDA Approval As First Treatment For Type Of Batten Disease The FDA approved the first treatment for the rare genetic disorder CLN2 disease that typically affects young children. What are the side effects of the therapy, and how much does it cost per year? by Allan Adamson
Health BioMarin To Halt Development Of $680M Duchenne Muscular Dystrophy Drug by Catherine Cabral-Isabedra
Healthy Living/Wellness BioMarin Drug Fails To Show Benefit In Inattention, Mood Complications Among Patients With PAH Deficiency by Angela Laguipo
Healthy Living/Wellness FDA Panel Not Persuaded By Effectiveness Of BioMarin Duchenne Muscular Dystrophy Drug by Angela Laguipo